Drug discovery programs built on regulated protein biology
Tamino Bio is applying its targeted protein modulation platform to disease areas where altered protein regulation, post-translational modification biology, and translational biomarkers can reveal new therapeutic strategies.
O-GlcNAc / OGT / OGA Signaling
Tamino Bio is grounded in O-GlcNAc biology, including OGT and OGA-mediated regulation of protein function, signaling state, metabolic response, and disease-relevant cellular behavior.
Targeted Modulation Screening
Tamino Bio is building discovery workflows to identify and prioritize molecules that modulate disease-relevant protein regulation, including enzyme activity, protein interactions, localization, stability, and PTM state.
Translational Biomarker Strategy
Multi-omic and biomarker readouts are built into Tamino’s approach to measure biological response, prioritize mechanisms, and support translational validation.
From platform biology to disease-focused programs
Tamino Bio is building drug discovery programs that connect molecular mechanism, targeted protein modulation, and disease-focused validation.
Mechanism-Guided Screening
Screening strategies are designed around disease-relevant protein regulation, OGT/OGA biology, PTM-state changes, and protein interaction networks.
Disease-Focused Models
Candidate mechanisms are tested in biological systems selected for translational relevance, with an initial emphasis on kidney disease biology and broader relevance across metabolic and chronic disease contexts.
Prioritized Therapeutic Strategies
Tamino Bio evaluates targeted modulation approaches that may restore, redirect, or selectively alter disease-relevant protein function.
Initial focus and platform expansion
Tamino Bio’s initial programs are anchored in O-GlcNAc-mediated protein regulation and kidney disease biology, with platform expansion across metabolic, fibrotic, neurodegenerative, cancer, and chronic disease contexts.
Initial Disease Focus
Tamino Bio’s initial disease focus is kidney biology, including disease contexts where O-GlcNAc signaling, metabolic regulation, cellular stress, and altered protein control intersect.
PTM-State Therapeutics
Tamino Bio is building strategies to evaluate how post-translational modification states, including O-GlcNAc and phosphorylation, influence disease mechanisms, target selection, and therapeutic response.
Translational Data Packages
Tamino Bio aims to build translational data packages that connect screening results, disease-model evidence, biomarker response, and therapeutic strategy.
